IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma

Area of Science:

• Immunology
• Oncology
• Hepatology

Background:

• Hepatocellular carcinoma (HCC) has poor survival rates and limited treatment options.
• Mechanisms regulating anticancer immunity in HCC are not fully understood.
• Inflammatory pathways are implicated in HCC development.

Purpose of the Study:

• To investigate the role of Interleukin-27 receptor (IL27R) signaling in hepatocellular carcinoma (HCC).
• To elucidate the mechanisms by which IL27R influences anticancer immunity in HCC.
• To explore the therapeutic potential of targeting the IL27 pathway in HCC.

Main Methods:

• In vivo studies using two hepatocarcinogenesis models.
• Analysis of IL27EBI3 cytokine and IL27RA expression in HCC patients.
• Assessment of innate cytotoxic lymphocyte activity and infiltration.
• Pharmacologic neutralization of IL27 signaling.

Main Results:

• IL27R signaling promotes HCC development in vivo.
• High IL27EBI3 or IL27RA expression correlates with poor HCC prognosis.
• IL27R restrains innate cytotoxic lymphocyte cytotoxicity within the tumor microenvironment.
• Blocking IL27 signaling enhances innate cytotoxic lymphocyte activity and reduces HCC.

Conclusions:

• IL27R acts as an immunologic checkpoint regulating innate cytotoxic lymphocytes in HCC.
• IL27R signaling promotes HCC development across different etiologies.
• Targeting the IL27 pathway represents a potential therapeutic strategy for HCC.